How the DMR Medical Device Targets the Duodenum

Duodenal mucosal resurfacing, or DMR, is an endoscopic medical device procedure that uses heat to ablate and regenerate the inner lining of the duodenum, the first segment of the small intestine, as a treatment for type 2 diabetes and related metabolic conditions. Unlike bariatric surgery, it does not alter the anatomy of the digestive tract. The device has received regulatory approval in Europe for type 2 diabetes and fatty liver disease and carries an FDA breakthrough device designation in the United States, though it is not yet widely available to patients outside of clinical trials and specialized centers.

How the Procedure Works

DMR is performed during an upper endoscopy, under sedation. The physician passes a specialized catheter through the working channel of the endoscope and into the duodenum. First, a submucosal lift catheter injects saline beneath the mucosal lining, creating a protective cushion that shields the deeper muscle layer from thermal injury. A second catheter then delivers circumferential hydrothermal ablation, heating the surface tissue to roughly 90°C for about ten seconds per treatment zone.¹ The physician works through a stretch of the duodenum, ablating successive segments in this fashion. The ablated mucosal layer then regenerates over the following weeks with healthier tissue. The whole procedure takes place through the mouth, requires no incisions, and patients typically go home the same day.

Why Target the Duodenum

The rationale behind DMR rests on a growing body of evidence that the duodenal lining itself becomes abnormal in people with obesity, high-fat diets, and type 2 diabetes. Preclinical and clinical analyses have identified changes in the duodenal mucosal layer that appear to be driven by dietary excess and are common among individuals with metabolic disease.² In animal models, high-fat and high-sugar diets cause the duodenal lining to thicken through elongation of the intestinal villi and deepening of the crypts, a process that increases the surface area available for nutrient absorption and triggers insulin resistance signaling.³

Mouse studies have made this more specific. When rodents are fed a Western-style diet, the duodenum develops focal hyperplasia with roughly a 40% increase in tissue weight and surface area, unlike other intestinal segments. The hyperplastic tissue shows an expanded population of hormone-producing enteroendocrine cells and gene-expression changes enriched for lipid and glucose metabolism pathways.⁴ These findings echo what bariatric surgeons noticed decades ago: procedures that bypass or exclude the duodenum from contact with food produce metabolic improvements that far exceed what weight loss alone would predict. DMR attempts to capture some of that benefit by resetting the mucosal lining endoscopically rather than rerouting the intestine surgically.⁵

What the Clinical Trials Show

The first international multicenter study, known as REVITA-1, enrolled people with inadequately controlled type 2 diabetes and followed them for up to two years. At six months after a single DMR procedure, average HbA1c dropped by about 1 percentage point, fasting blood sugar fell, and insulin resistance improved substantially. Liver enzyme levels also decreased. These improvements held through 12 months and remained durable at 24 months, with HbA1c levels staying around 7.5% while more than half of patients had their diabetes medications reduced or unchanged.⁶ One notable finding was that the HbA1c improvement did not correlate with weight loss, which was modest at about 2.5 kilograms, suggesting the metabolic benefit comes from the mucosal change itself rather than calorie restriction.⁷

The stronger test came with REVITA-2, the first randomized, sham-controlled trial. This matters because endoscopic procedures carry a significant placebo effect; patients who believe they received a treatment often improve even if the treatment was inert. In the overall study population, the difference between the DMR group and the sham group in HbA1c reduction did not reach statistical significance. However, the picture differed by region: European patients who received DMR saw a significantly greater HbA1c reduction compared to sham, while a large placebo response among Brazilian participants diluted the overall result. Among all patients with particularly high fasting blood sugar at baseline, DMR produced significantly greater HbA1c reductions than sham.⁸ These findings suggest that DMR works best in patients with more severe metabolic disruption, but the mixed overall result means the evidence base is still evolving.

A 2025 systematic review and meta-analysis pooling data across studies found a mean HbA1c reduction of about 1.1 percentage points at six months in patients with inadequately controlled type 2 diabetes, with serious adverse events pooled at roughly 2%.⁹ That HbA1c reduction sits in a meaningful clinical range, comparable to what some oral diabetes medications achieve, though the heterogeneity across studies was high.

How Long the Effects Last

One of the biggest practical questions about DMR is whether a single procedure produces lasting benefit or whether the effect wears off as the new mucosa ages. The REVITA-1 two-year data are encouraging: improvements in blood sugar control, liver enzymes, HDL cholesterol, and triglyceride ratios persisted over the full follow-up period.¹⁰

Longer follow-up data come from a study that combined DMR with liraglutide, a GLP-1 receptor agonist. At four years after the procedure, nine out of 14 patients (64%) remained off insulin entirely, and weight and BMI were significantly lower than at baseline. Five of those patients (36% of the total group) maintained adequate glycemic control at the four-year mark without insulin.¹¹ Because that study used a combination approach, it is hard to separate how much of the long-term benefit belongs to DMR alone versus the drug. Still, the fact that most patients in that cohort stayed off insulin years later is striking for a single endoscopic procedure.

Safety Profile

Across the published trials, DMR has shown a reassuringly mild adverse event profile. Most side effects are transient and consistent with what you would expect from any therapeutic upper endoscopy: sore throat, mild abdominal discomfort, nausea in the first day or two. A multicenter implementation study reported no cases of duodenal stenosis after the procedure technique was refined in its early iterations.¹² The REVITA-2 sham-controlled trial similarly described most adverse events as mild and short-lived.¹³ The meta-analysis put the pooled serious adverse event rate at about 2%.¹⁴

Early versions of the procedure did encounter problems, particularly duodenal narrowing, which is why the technique was modified before the larger studies began. That procedural evolution is worth knowing about: the DMR device and protocol used in the more recent trials are not identical to the first-generation approach, and the safety data reflect the improved version. As with any endoscopic thermal treatment, the main risks are perforation and bleeding, but neither has appeared at rates that raised red flags in the published cohorts.

Effects on Liver Fat

Because fatty liver disease and type 2 diabetes share underlying metabolic drivers, researchers have tested whether DMR can also reduce liver fat. The results here are weaker. The REVITA-2 trial found that European patients in the DMR group had a statistically significant reduction in liver fat (measured by MRI) compared to sham at 12 weeks, with a median decrease of about 5.4% versus 2.2% in the sham arm.¹⁵ But a dedicated pilot study in patients with non-alcoholic steatohepatitis (NASH) was disappointing. The primary endpoint of NASH resolution without worsening fibrosis was not met by any patient, and liver fat measurements on MRI did not change meaningfully at six or 12 months after DMR.¹⁶ A pooled analysis of DMR’s metabolic influence on fatty liver disease similarly found no statistically significant changes in liver fat fraction, HbA1c, or insulin resistance when all available data were combined.¹⁷

This disconnect is interesting. DMR seems to improve liver enzyme levels (which are a marker of liver inflammation) quite consistently, but the direct reduction of fat deposited in the liver has not been reliably demonstrated. One possible explanation is that the enzyme improvements reflect reduced inflammatory signaling rather than physical clearance of fat from liver cells. The European approval for fatty liver disease got ahead of the clinical evidence somewhat, and larger trials are needed before DMR can be confidently recommended for liver-specific outcomes.

Combining DMR With GLP-1 Drugs

Some of the most provocative data involve pairing DMR with a GLP-1 receptor agonist like liraglutide, the same class of drug that includes semaglutide. In a study of 16 patients with insulin-dependent type 2 diabetes, the combination of DMR plus a GLP-1 drug allowed 69% of patients to discontinue insulin entirely while improving metabolic health. The researchers found that the combination treatment increased postprandial unconjugated bile acids, suggesting that DMR may alter bile acid signaling pathways in ways that complement GLP-1 therapy.¹⁸ Getting almost seven out of ten insulin-dependent patients off insulin is a dramatic outcome, though the study was small and uncontrolled. If the bile acid mechanism holds up, it could explain why DMR and GLP-1 agonists seem to complement each other: they may be hitting different points on the same metabolic circuit.

Gut Microbiome Changes

Given the growing interest in how gut bacteria influence metabolism, researchers also looked at whether DMR reshapes the microbiome. A pilot study in patients receiving DMR combined with a GLP-1 agonist found no significant change in gut microbial diversity or community composition at three months compared to baseline, and no individual bacterial species shifted meaningfully.¹⁹ This is a small study with short follow-up, so it is not the final word. But it tentatively suggests that the metabolic improvements from DMR are driven by changes in the mucosal tissue and its signaling rather than by a dramatic remodeling of the bacterial population in the gut.

Patient Experience and Quality of Life

Clinical trials tend to report biomarker changes, but what patients actually feel matters too. The REVITA-1 study reported that diabetes treatment satisfaction scores improved significantly after DMR.²⁰ A published case report described a patient who experienced increased energy, improved mood, and better overall quality of life following the procedure, with no adverse events such as nausea, abdominal pain, or gastrointestinal bleeding.²¹ These are individual-level observations, not robust quality-of-life data from randomized trials, so they should be read cautiously. But for a procedure that requires no ongoing adherence after the initial endoscopy, the appeal to patients managing complex medication regimens is obvious.

Where DMR Fits in the Regulatory Landscape

DMR is now approved in Europe for type 2 diabetes and fatty liver disease and has received FDA breakthrough device designation, a regulatory pathway that accelerates development and review for devices addressing serious conditions with unmet needs.²² Breakthrough designation does not mean the FDA has approved DMR for use in the United States. It means the agency recognizes the potential and has agreed to expedite the review process. Pivotal trials needed for full FDA approval are ongoing, and it could still be several years before the procedure becomes routinely available to American patients.

This regulatory asymmetry between Europe and the U.S. reflects different evidentiary standards and approval pathways for medical devices. European CE marking can sometimes be obtained with less extensive trial data than the FDA requires. For patients and physicians in the U.S., the practical implication is that DMR remains an investigational procedure accessible primarily through clinical trial enrollment.

When DMR Does Not Seem to Work

Not every metabolic condition responds to DMR. A trial in women with polycystic ovary syndrome (PCOS) and insulin resistance tested whether the procedure could improve insulin sensitivity in this population. It did not. Insulin sensitivity measured by clamp testing showed no significant difference between the DMR and sham groups, and insulin resistance markers at 24 weeks were similarly unchanged.²³ There was a trend toward improved menstrual regularity in the DMR group, which is clinically relevant for PCOS, but it did not reach statistical significance.

The researchers concluded that DMR may exert its effects only in the context of high blood sugar or pathologically thickened duodenal mucosa, conditions that were not necessarily present in these women who had insulin resistance but normal glucose levels.²⁴ This finding is actually informative about the mechanism. It suggests DMR is not a general-purpose insulin sensitizer. Instead, it appears to work specifically by addressing the mucosal abnormalities that develop when the duodenum is exposed to chronic hyperglycemia and dietary excess. In people whose duodenal lining has not undergone those changes, ablating it and letting it regrow may accomplish nothing. The REVITA-2 finding that patients with the highest fasting glucose benefited most from DMR fits the same pattern: the worse the metabolic disruption, the more the procedure has to correct.